[Placental transfer of monoclonal antibodies: The example of anti-TNF alpha drugs]

D Beghin

doi:10.1016/j.gofs.2021.06.008

[Placental transfer of monoclonal antibodies: The example of anti-TNF alpha drugs]

Gynecol Obstet Fertil Senol. 2021 Sep;49(9):724-726. doi: 10.1016/j.gofs.2021.06.008. Epub 2021 Jun 29.

[Article in French]

Author

D Beghin¹

Affiliation

¹ Centre de référence sur les agents tératogènes (CRAT), DMU Épidémiologie et biostatistique, Santé publique, Pharmacie, Pharmacologie, Recherche, Information médicale, Thérapeutique et médicaments (ESPRIT), GHU, AP-HP, Sorbonne université - site Trousseau, 26, avenue Dr-Netter, 75571 Paris cedex 12, France. Electronic address: [email protected].

PMID: 34214735
DOI: 10.1016/j.gofs.2021.06.008

Abstract

Anti-TNF alpha monoclonal antibodies are used in the treatment of chronic inflammatory diseases, which commonly affect women of childbearing age. Due to their similar structure to native immunoglobulins, the evaluation of their placental transfer by a pharmacological approach of the mechanisms involved is an interesting source of information, useful to the risk-benefit assessment of drugs in pregnant women.

Keywords: Anti-TNF alpha; FcRn; Immunoglobulines; Immunoglobulins; Placenta.

MeSH terms

Antibodies, Monoclonal* / pharmacokinetics
Female
Humans
Maternal-Fetal Exchange*
Placenta
Pregnancy
Tumor Necrosis Factor Inhibitors* / pharmacokinetics

Substances

Antibodies, Monoclonal
Tumor Necrosis Factor Inhibitors